Pfizer’s 2026 Outlook
Revenue Guidance: $59.5-62.5 billion Adjusted EPS: $2.80-3.00 Current Price Context: At recent trading around $25-26/share, this implies a forward P/E of roughly 8.3-9.3x
Key Growth Drivers
1. Pipeline Catalysts (Major Near-Term)
- ~20 pivotal trial starts planned for 2026
- Ultra-long-acting GLP-1 (obesity): Phase 2b showing robust monthly dosing results
- Padcev (oncology): Multiple approvals in bladder cancer expanding market
- Braftovi: New colorectal cancer indication data
- 10 pivotal trials for Metsera obesity assets ($7B acquisition)
2. Revenue Composition
- Non-COVID portfolio growing 6% operationally (solid base)
- COVID products: ~$5B expected (declining but stabilizing)
- Loss of exclusivity headwind: ~$1.5B negative impact
3. Strong Performers
- Vyndaqel family (heart disease): 7% growth
- Eliquis (anticoagulant): 8% growth
- Padcev (oncology): 15% growth
- Prevnar (pneumococcal): 8% growth
Industry Comparison
Large-Cap Pharma Peers
Eli Lilly (LLY)
- 2026E Revenue: ~$58-62B (similar size)
- Growth Rate: 20%+ driven by obesity (Mounjaro/Zepbound)
- P/E: ~50x (significantly higher valuation)
- Key Difference: Lilly dominates obesity market NOW; Pfizer is 2-3 years behind
Novo Nordisk (NVO)
- Obesity leader with Ozempic/Wegovy
- Trading at premium multiples (30-35x)
- Pfizer’s GLP-1 won’t compete until 2027-2028 at earliest
Merck (MRK)
- Similar valuation (low teens P/E)
- Strong oncology (Keytruda) but facing LOE in 2028
- More stable, less upside potential than Pfizer
Bristol-Myers Squibb (BMY)
- Lower valuation (~8-10x P/E)
- Similar challenges with LOE and pipeline execution
- Comparable risk/reward profile
Johnson & Johnson (JNJ)
- More diversified (devices, consumer)
- Higher quality rating, lower growth
- P/E around 14-16x
Pfizer-Specific Factors
Positives
- Deeply undervalued vs. historical norms (traded 15-20x P/E pre-COVID)
- Pipeline richness: 11 pivotal starts in 2025, 20 planned for 2026
- Obesity optionality: If GLP-1 succeeds, massive upside (but years away)
- 3.5% dividend yield provides downside support
- $8.8B in business development shows aggressive growth stance
Negatives
- Execution risk: Track record of pipeline disappointments
- Obesity timeline: 2027-2028 before meaningful revenue
- COVID dependency: Still $5B (8% of revenue) from declining products
- Political headwinds: TrumpRx pricing pressure, tariff concerns
- Intangible impairments: $4.4B Q4 2025 writedowns signal judgment issues
Conservative Projection (2026-2028)
2026:
- Revenue: $61B (midpoint)
- EPS: $2.90 (midpoint)
- Stock: $26-32 range (9-11x P/E)
2027:
- Revenue: $63-65B (low single-digit growth)
- EPS: $3.10-3.30
- Stock: $28-36 (assuming market gives 10-11x on improving pipeline)
2028:
- Revenue: $67-72B (if GLP-1 launches successfully)
- EPS: $3.50-4.00
- Stock: $35-48 (if obesity story gains traction, multiple expands to 12-14x)
Investment Verdict
Compared to Industry
Pfizer is a VALUE play, not a GROWTH play (unlike Lilly/Novo)
Better than: BMY (similar challenges, weaker pipeline) Similar to: MRK (good value, execution risk) Worse than: LLY/NVO (but trading at 1/5 the valuation) More conservative than: JNJ (but higher upside potential)
Risk-Adjusted Return Scenarios
Bull Case (30% probability): $45-50 by 2028
- GLP-1 succeeds, pipeline delivers, multiple re-rates to 14x
- 3-year return: ~90%
Base Case (50% probability): $32-38 by 2028
- Modest growth, pipeline mixed results, dividend sustained
- 3-year return: ~35-40%
Bear Case (20% probability): $22-26 by 2028
- Pipeline failures, obesity flops, COVID evaporates faster
- 3-year return: Flat to -15%
Bottom Line
Pfizer offers asymmetric risk/reward at current prices. The market is pricing in minimal pipeline success and no obesity upside. Given the dividend floor, downside is limited to ~15-20%, while upside could be 50-90% if even half the pipeline delivers.
For a Protected Wheel/Collar strategy: PFE is excellent due to:
- High implied volatility (option premiums rich)
- Strong dividend support
- Clear technical support levels
- Low correlation to high-flying tech
Relative to industry: It’s the cheapest major pharma with the most catalysts over the next 24 months. Whether those catalysts deliver is the $100B question.
The Hedge 